Apitegromab: could it preserve muscle during tirzepatide weight loss?

Direct answer

In the phase 2 EMBRAZE trial, adults losing weight on tirzepatide who also received apitegromab lost 1.9 kg less lean mass than those on tirzepatide plus placebo, with similar total weight loss. Apitegromab is investigational and is not an approved obesity treatment.

What apitegromab is

Apitegromab is a fully human monoclonal antibody that selectively inhibits the activation of latent myostatin. Myostatin is a natural brake on skeletal muscle growth; blocking its activation releases that brake. The drug was originally developed in spinal muscular atrophy and is now being tested in the very different setting of pharmacological weight loss.

The rationale is straightforward: tirzepatide drives the weight and fat loss, while apitegromab is intended to limit the lean-mass loss that accompanies it.

The EMBRAZE trial

A randomised, double-blind, placebo-controlled phase 2 trial published in Nature Medicine on 8 June 2026 (Pratley RE et al.; NCT06445075).

• Participants: 102 adults with overweight or obesity, enrolled June–September 2024
• Randomisation: 1:1 to tirzepatide + apitegromab, or tirzepatide + placebo
• Tirzepatide: escalated by 2.5 mg every 4 weeks to a maximum maintenance dose of 15 mg weekly
• Apitegromab: 10 mg/kg intravenously
• Duration: 24 weeks, with assessment continuing to week 32

Results at week 24:

• 1.9 kg (80% CI 1.2–2.7) less lean mass loss with apitegromab (P = 0.001)
• 54.9% retention of lean mass relative to placebo
• Lean mass made up 14.6% of total weight lost with apitegromab, versus 30.2% with placebo
• Fat accounted for 85.3% of weight lost versus 69.5% on placebo
• Total body weight loss was similar between groups

Safety: adverse events occurred in 39/51 (76%) on apitegromab and 36/51 (71%) on placebo. Serious adverse events were balanced at 1/51 (2%) in each arm.

What this shows — and what it does not

The trial demonstrates that apitegromab shifted the composition of weight loss: less lean tissue lost, proportionally more fat. That is a meaningful finding.

It does not show that apitegromab builds muscle in people with obesity. Preventing loss is not the same as producing gain. Nor does it show improved strength or physical function — DXA-measured lean body mass includes organs, bone and body water, not only skeletal muscle, and the trial was not designed or sized to prove functional benefit. Nor does it show any improvement in weight loss itself; total weight loss was unchanged.

Twenty-four weeks is also short, and 102 participants is small. These are phase 2 signals, not conclusions.

Why it could matter clinically

Composition of weight loss matters most in the patients I worry about: those losing very large amounts of weight, older adults, anyone already at risk of sarcopenia, and patients expected to stay on pharmacological treatment for years. In those groups, preserving lean tissue could plausibly protect metabolic rate, glucose handling and independence — but that has to be demonstrated, not assumed.

Regulatory status

Apitegromab is not approved for obesity or weight management in any jurisdiction, including Kuwait. It is available only through clinical trials. Anything marketed online under this name should be treated as illegitimate.

Frequently asked questions

What is apitegromab?

An investigational monoclonal antibody that selectively inhibits activation of latent myostatin, a protein that limits skeletal muscle growth.

Does apitegromab prevent muscle loss with tirzepatide?

In EMBRAZE it reduced lean-mass loss by 1.9 kg over 24 weeks versus placebo, retaining about 55% of the lean mass that would otherwise have been lost.

What is the EMBRAZE trial?

A 102-participant, randomised, double-blind, placebo-controlled phase 2 trial of apitegromab with tirzepatide, published in Nature Medicine in June 2026.

Is apitegromab approved for weight loss?

No. It is investigational for this use as of August 2026.

Does tirzepatide cause muscle loss?

Some lean mass is lost with any large weight loss. In the placebo arm of EMBRAZE, lean mass accounted for 30.2% of total weight lost.

Could apitegromab become part of obesity treatment?

Possibly, but phase 3 trials measuring strength and physical function — not just DXA lean mass — are needed first.

This article is educational and does not replace personalized medical advice. Contact Professor Jamal's clinic on WhatsApp +965 60621662.

Reference: Pratley RE et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, 2026. PMID 42260100.